Press coverage about Juno Therapeutics (NASDAQ:JUNO) has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Juno Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.7252296625746 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Robbins Arroyo LLP: Juno Therapeutics, Inc. (JUNO) Misled Shareholders According to a Recently Filed Shareholder … – Business Wire (press release) (businesswire.com)
- Rocking Stocks: Nabors Industries Ltd. (NYSE:NBR), Juno Therapeutics, Inc. (NASDAQ:JUNO), Fairmount Santrol … – The Stock Street (press release) (thestreetpoint.com)
- Juno Therapeutics Inc (NASDAQ: JUNO) – Hot Stock That Must Be in Your Portfolio – Alpha Beta Stock (alphabetastock.com)
- Brokerages Anticipate Juno Therapeutics, Inc. (JUNO) Will Announce Quarterly Sales of $23.86 Million (americanbankingnews.com)
A number of brokerages have weighed in on JUNO. Cowen and Company restated a “buy” rating on shares of Juno Therapeutics in a report on Friday, November 3rd. Raymond James Financial, Inc. upped their target price on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Citigroup Inc. reiterated a “buy” rating and issued a $59.00 target price on shares of Juno Therapeutics in a research note on Tuesday, October 31st. Finally, SunTrust Banks, Inc. upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 2nd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $44.20.
Juno Therapeutics (NASDAQ:JUNO) traded up $2.54 on Thursday, reaching $56.40. 1,776,000 shares of the company traded hands, compared to its average volume of 2,063,072. Juno Therapeutics has a 52 week low of $17.52 and a 52 week high of $61.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The company had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same period last year, the company posted ($0.57) earnings per share. Juno Therapeutics’s quarterly revenue was up 115.4% on a year-over-year basis. research analysts predict that Juno Therapeutics will post -4.02 EPS for the current year.
In related news, EVP Robert Azelby sold 6,666 shares of Juno Therapeutics stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Following the completion of the sale, the executive vice president now owns 79,998 shares in the company, valued at approximately $4,395,890.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard Klausner sold 12,000 shares of Juno Therapeutics stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $42.66, for a total transaction of $511,920.00. Following the sale, the director now owns 783,536 shares of the company’s stock, valued at approximately $33,425,645.76. The disclosure for this sale can be found here. Insiders sold a total of 79,670 shares of company stock valued at $3,553,777 over the last three months. Corporate insiders own 15.26% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Juno Therapeutics (JUNO) Getting Somewhat Favorable Press Coverage, Analysis Shows” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/11/16/juno-therapeutics-juno-getting-somewhat-favorable-press-coverage-analysis-shows.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.